Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Teijin Earns Japan Rights to Novel Botulinum Toxin
October 13, 2017
- Ono Grabs Rights to 2 XPO1 Inhibitors in Japan, Asia
October 13, 2017
- Daiichi Sankyo Initiates AMED-Funded Joint Research on Genetic Vaccine Platform with NIBIOHN
October 13, 2017
- LEO Pharma to Offer Cell Assays in Japan to Evaluate External Compounds under Unique Open Innovation Model
October 13, 2017
- FGF23 Antibody Burosumab Earns FDA Priority Status: Kyowa Kirin/Ultragenyx
October 12, 2017
- FDA Fast-Tracks Astellas’s AML Med Gilteritinib
October 12, 2017
- 3 Japan Drug Majors Launch Open Innovation Program for Drug Repositioning
October 12, 2017
- Harada Picked as Next Pfizer Japan President
October 12, 2017
- Bayer to Set Up Collaboration Research Center in Kobe in Early 2018 to Support Startups
October 12, 2017
- NanoCarrier, JCR to Collaborate on Brain Drug Delivery
October 11, 2017
- Hisamitsu Sees Lower Ethical Drug Sales in March-August
October 11, 2017
- Takeda Promoting Digital Innovations through IT Industry Approaches: Digital Acceleration Head
October 11, 2017
- Zytiga Gets Priority Review Status for Earlier Use in Prostate Cancer
October 11, 2017
- Torii to Skip November Listing of Tablet-Form Pollen Allergy Therapy
October 10, 2017
- Kyowa Kirin Pulls Plug on Tivantinib, Follows Daiichi Sankyo
October 10, 2017
- Nippon Kayaku Clinches Supreme Court Victory in Elplat Patent Suit
October 6, 2017
- AZ to Transfer Migraine Med Zomig to Sawai Mid-Next Year
October 6, 2017
- Daiichi Sankyo, Osaka Univ. Spin-Off to Jointly Develop iPS Cell-Derived Cardiomyocyte Sheet, Aiming at Commercialization within 5 Years
October 6, 2017
- Sanofi Files Spiramycin for Congenital Toxoplasmosis
October 6, 2017
- Nipro Aims at 100 Billion Yen Sales for Pharma Biz by FY2020, Seeking No. 1 Spot among Research-Oriented Makers in Generic Field
October 5, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…